Virginia Retirement Systems ET AL lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 88.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,800 shares of the company’s stock after acquiring an additional 7,900 shares during the quarter. Virginia Retirement Systems ET AL’s holdings in Neurocrine Biosciences were worth $1,418,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Emory University boosted its holdings in Neurocrine Biosciences by 11.9% during the first quarter. Emory University now owns 28,287 shares of the company’s stock worth $2,492,000 after buying an additional 2,998 shares in the last quarter. Steinberg Global Asset Management boosted its holdings in Neurocrine Biosciences by 2.7% during the first quarter. Steinberg Global Asset Management now owns 15,923 shares of the company’s stock worth $1,403,000 after buying an additional 412 shares in the last quarter. Exane Derivatives boosted its holdings in Neurocrine Biosciences by 901.4% during the first quarter. Exane Derivatives now owns 4,857 shares of the company’s stock worth $428,000 after buying an additional 4,372 shares in the last quarter. Enterprise Financial Services Corp boosted its holdings in Neurocrine Biosciences by 9,375.0% during the first quarter. Enterprise Financial Services Corp now owns 6,064 shares of the company’s stock worth $535,000 after buying an additional 6,000 shares in the last quarter. Finally, Nordea Investment Management AB boosted its holdings in Neurocrine Biosciences by 1.2% during the first quarter. Nordea Investment Management AB now owns 38,996 shares of the company’s stock worth $3,435,000 after buying an additional 465 shares in the last quarter. Institutional investors and hedge funds own 95.82% of the company’s stock.
A number of brokerages recently weighed in on NBIX. JPMorgan Chase & Co. upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $100.00 to $106.00 in a report on Monday, April 22nd. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, July 31st. Stifel Nicolaus set a $113.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Monday, July 15th. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Thursday. Finally, Credit Suisse Group raised their target price on shares of Neurocrine Biosciences from $95.00 to $110.00 and gave the stock an “outperform” rating in a report on Tuesday, July 30th. Three analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $107.15.
Neurocrine Biosciences stock traded down $2.35 during midday trading on Friday, reaching $95.50. The stock had a trading volume of 512,726 shares, compared to its average volume of 796,401. The firm has a fifty day moving average of $87.66. Neurocrine Biosciences, Inc. has a twelve month low of $64.72 and a twelve month high of $126.98. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.44. The firm has a market cap of $8.96 billion, a price-to-earnings ratio of 434.09, a price-to-earnings-growth ratio of 5.10 and a beta of 1.32.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Monday, July 29th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.13. Neurocrine Biosciences had a net margin of 2.98% and a return on equity of 0.46%. The firm had revenue of $183.58 million during the quarter, compared to analyst estimates of $161.79 million. During the same quarter last year, the business posted ($0.07) EPS. The company’s revenue was up 89.5% on a year-over-year basis. As a group, research analysts predict that Neurocrine Biosciences, Inc. will post 0.8 EPS for the current fiscal year.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Further Reading: What is a capital gains distribution?
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.